Home / Science / Gut's Immune Protein: Friend or Foe?
Gut's Immune Protein: Friend or Foe?
19 Oct
Summary
- A single protein, RelB, plays opposite roles in gut immunity.
- RelB helps fend off bacteria but can worsen inflammation.
- Understanding RelB's context is vital for new gut disease treatments.
New research from the National Institute of Immunology in New Delhi has unveiled a complex role for the protein RelB in the gut's immune system. This protein acts as a gatekeeper, crucial for developing specialized cells that produce IL-23, a molecule that triggers inflammation to combat threats like harmful bacteria.
However, RelB's function is context-dependent. While it aids in building a protective army in the intestinal wall, it simultaneously suppresses regulatory T-cells, the immune system's peacekeepers, in nearby lymph nodes. This 'Jekyll-and-Hyde' behavior means that a drug targeting an overactive immune response might unintentionally weaken the gut's defenses against pathogens.
Scientists discovered that RelB initiates a cascade involving another protein, RBP-J, which is essential for immature cells to mature into IL-23-producing sentinels. This indicates a cooperation between RelB and another signaling network, previously thought to be independent, to arm the gut.
The dual action of RelB presents a delicate challenge for drug development. While IL-23 blocking drugs are used for inflammatory bowel disease, targeting RelB requires a nuanced approach due to its opposing effects. Further research is needed to fully understand its role, especially in human patients, before it can be reliably considered for therapeutic interventions.
